Clinical trial
An Observational Study On Metabolic Syndrome Parameters In Schizophrenia…
NCT00448630 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00448630 |
|---|---|
| Title | An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics |
| Official title | A MULTI-CENTER, NON-INVASIVE OBSERVATIONAL STUDY OF METABOLIC SYNDROME PARAMETERS IN SCHIZOPHRENIC PATIENTS USING ATYPICAL ANTIPSYCHOTICS |
| Acronym | MESSAGE |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Schizophrenia, Metabolic Syndrome X |
| Intervention type | Other |
| Interventions | No intervention |
| Enrollment | 328 |
| Start date | Oct 23, 2007 |
| Primary completion | Jul 30, 2008 |
| Completion | Jul 30, 2008 |
| First posted | Mar 19, 2007 |
| Last update posted | May 3, 2022 |
| Countries | Turkey (Türkiye) |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: